Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Mental Disorders × Amifampridine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Rare Diseases 1 Neurologic Manifestations 1 Mental Disorders 1 Lambert-Eaton Myasthenic Syndrome 1

Interventions

Standard of Care 2 Selective Serotonin Reuptake Inhibitors 1 Methylphenidate 1 Memory and Learning Tests 1 Interviews as Topic 1 Immunoglobulins 1 Forest Therapy 1 Dialectical Behavior Therapy 1 Cognitive Behavioral Therapy 1 Citalopram 1 Behavior Therapy 1 Amifampridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡